« Return to News | Clinical Intelligence

Paratek, FDA agrees on Special Protocol Assessment for pneumonia study

Wednesday, March 28, 2012 12:51 PM

Paratek Pharmaceuticals has reached agreement with the FDA on its second Special Protocol Assessment (SPA) related to the phase III program design for the company's lead antibiotic candidate, omadacycline (formerly PTK 0796), this time for community-acquired bacterial pneumonia (CABP).

Omadacycline is a broad-spectrum, first-in-class aminomethylcycline antibiotic with oral and IV formulations that address the leading organisms that cause bacterial infections such as CABP and serious (acute) bacterial skin and skin structure infections (ABSSSI).

This agreed upon SPA, and previous one for ABSSSI, designate the trials’ design as double-blind, randomized and controlled and will compare omadacycline to the standard of care therapies. The agreed upon SPA means the FDA can not alter its perspective on the issues of design, execution or analyses of the trial.

"This is the first SPA agreement for CABP under the FDA's new early response endpoint that we are aware of, and we believe that it clarifies the regulatory path to approval and supports the appropriateness of omadacycline for these two important infections (ABSSSI and CABP)," said Dr. Gary J. Noel, chief medical officer, Paratek. 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.